Congestive Heart Failure and Treatment in Thalassemia Major

REFERENCES

• Weatherall DJ, Clegg JB. Inherited hemoglobin disorders: an increasing global health problem. Bull World Health Org 2001; 79(8)704–712
   PubMed Web of Science ®Google Scholar
• Olivieri NF. The β-thalassemias. N Engl J Med 1999; 341(2)99–109
   PubMed Web of Science ®Google Scholar
• Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99(1)36–43
   PubMed Web of Science ®Google Scholar
• Kanavakis E, Traeger-Synodinos J, Tzetis M, Metaxotou-Mavromati A, Ladis V, Kattamis C. Molecular characterization of homozygous (high Hb A2) β-thalassemia intermedia in Greece. Pediatr Hematol Oncol 1995; 12(1)37–45
   PubMed Web of Science ®Google Scholar
• Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica 1995; 80(1)58–68
   PubMed Web of Science ®Google Scholar
• Galanello R, Cao A. Relationship between genotype and phenotype. Thalassemia intermedia. Ann NY Acad Sci 1998; 850: 325–333
   PubMed Web of Science ®Google Scholar
• Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia major. Cooleycare Programme. Lancet 1991; 337(8736)277–280
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355(9220)2051–2052
   PubMed Web of Science ®Google Scholar
• Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood 2004; 104(1)34–39
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89(10)1187–1193
   PubMed Web of Science ®Google Scholar
• Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104(1)263–269
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin 2006; 30(2)219–227
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004; 73(5)359–366
   PubMed Web of Science ®Google Scholar
• Fitchett DH, Coltart DJ, Littler WA, Leyland MJ, Trueman T, Gozzard DI, Peters TJ. Cardiac involvement in secondary haemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovasc Res 1980; 14(12)719–724
   PubMedGoogle Scholar
• Barosi G, Arbustini E, Gavazzi A, Grasso M, Pucci A. Myocardial iron grading by endomyocardial biopsy. Eur J Hematol 1989; 42(4)382–388
   PubMedGoogle Scholar
• Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005; 106(9)3242–3250
   PubMed Web of Science ®Google Scholar
• Westwood MA, Sheppard MN, Awogbade M, Ellis G, Stephens AD, Pennell DJ. Myocardial biopsy and T2* magnetic resonance in heart failure due to thalassaemia. Br J Haematol 2005; 128(1)2
   PubMedGoogle Scholar
• Kyriacou K, Michaelides Y, Senkus R, Simamonian K, Pavlides N, Antoniades L, Zambartas C. Ultrastructural pathology of the heart in patients with β-thalassemia major. Ultrastruct Pathol 2000; 24(2)75–81
   PubMed Web of Science ®Google Scholar
• Hahalis G, Manolis AS, Apostolopoulos D, Alexopoulos D, Vagenakis AG, Zoumbos NC. Right ventricular cardiomyopathy in β-thalassemia major. Eur Heart J 2002; 23(2)147–156
   PubMed Web of Science ®Google Scholar
• Pepe A, Positano V, Santarelli MF, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging 2006; 23(5)662–668
   PubMed Web of Science ®Google Scholar
• Forni GL, Derchi G. Typical manifestation of acute congestive heart failure in patients with thalassaemia major causing diagnostic delay in the emergency room. Eur J Heart Fail 2003; 5(5)607–608
   PubMedGoogle Scholar
• Borer JS, Henry WL, Epstein SE. Echocardiographic observations in patients with systemic infiltrative disease involving the heart. Am J Cardiol 1977; 39(2)184–188
   PubMed Web of Science ®Google Scholar
• Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characteristics in β-thalassemia major. Circulation 1993; 88(3)1127–1135
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22(23)2171–2179
   PubMed Web of Science ®Google Scholar
• Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis 2006; 6(4)226–233
   PubMedGoogle Scholar
• Sermsappasuk P, Baek M, Weiss M. Kinetic analysis of myocardial uptake and negative inotropic effect of amiodarone in rat heart. Eur J Pharm Sci 2006; 28(3)243–248
   PubMedGoogle Scholar
• Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006; 91(9)1159–1161
   PubMedGoogle Scholar
• Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis 2006; 36(1)21–25
   PubMed Web of Science ®Google Scholar
• Tsironi M, Korovesis K, Farmakis D, Deftereos S, Aessopos A. Hypocalcemic heart failure in thalassemic patients. Int J Hematol 2006; 83(4)314–317
   PubMedGoogle Scholar
• Littera R, La Nasa G, Derchi G, Cappellini MD, Chang CY, Contu L. Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood 2002; 100(4)1516–1517
   PubMedGoogle Scholar
• Derchi G, Forni GL, Formisano F, Cappellini MD, Galanello R, D'Ascola G, Bina P, Magnano C, Lamagna M. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 2005; 90(4)452–458
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350(9)886–895
   PubMed Web of Science ®Google Scholar
• Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005; 74(1)84–85
   PubMedGoogle Scholar
• Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in β-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107(9)738–744
   Google Scholar
• Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJ. High incidence of cardiomyopathy in β thalassemia patients receiving regular transfusion and iron chelation; reversal by intensified chelation. Acta Haematol 1990; 84(3)113–117
   PubMed Web of Science ®Google Scholar
• Mourad HF, Hoffbrand VA, Sheikh-Taha M, Koussa S, Khoriaty IA, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overload thalassaemia patients. Br J Haematol 2003; 121(1)187–189
   PubMed Web of Science ®Google Scholar
• Kontoghiorges JG, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000; 23(3)211–223
   PubMedGoogle Scholar
• Wood JC, Tyszka M, Carson S, Nelson M, Coates T. Myocardial iron loading in transfusion dependent thalassemia and sickle-cell disease. Blood 2004; 103(5)1934–1936
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107(9)3733–3737
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Lancet 2002; 360(9332)516–520
   PubMed Web of Science ®Google Scholar
• Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91(7)873–880
   PubMed Web of Science ®Google Scholar